Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: one- year outcomes in a multicenter study (CROSBI ID 732337)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Martin, A. ; Brešković, Toni ; Ouss, A. ; Dekker, L. ; Yap, S. C. ; Bhagwandien, R. ; Cielen, N. ; Albrecht, E. M. ; Richards, E. ; Tran, B. et al. Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: one- year outcomes in a multicenter study // European heart journal. 2021. str. 369-369

Podaci o odgovornosti

Martin, A. ; Brešković, Toni ; Ouss, A. ; Dekker, L. ; Yap, S. C. ; Bhagwandien, R. ; Cielen, N. ; Albrecht, E. M. ; Richards, E. ; Tran, B. ; Lever, N. ; Anić, Ante

engleski

Novel cryoballoon to isolate pulmonary veins in patients with paroxysmal atrial fibrillation: one- year outcomes in a multicenter study

Background: Recently, a novel cryoballoon (CB ; POLARx) has been developed with increased steerability which maintains size and pressure throughout the ablation. Initial clinical data has demonstrated acute procedural safety and efficacy in de novo pulmonary vein isolation (PVI) procedures in patients with paroxysmal atrial fibrillation (AF). However, there are limited studies demonstrating the long-term efficacy of the CB. Purpose: To evaluate the long-term safety and efficacy of the novel CB in treating paroxysmal AF. Methods: This was a non-randomized, prospective, multi-center study. Fifty-eight consecutive patients with paroxysmal AF were enrolled at 4 centers for de novo PVI procedures. Cryoablation was delivered for 180s if time to isolation was ≤60s. Otherwise a 240s cryoablation was performed. PVI was confirmed with entrance and exit block testing. Patients were followed for 1 year with 24-hour Holter monitoring at 3, 6, and 12 months. After a 3- month blanking period, recurrence was defined as having any documented, symptomatic episode(s) of AF or atrial tachycardia. Results: Acute isolation with the CB was achieved in 230 of 231 pulmonary veins (99.6%) with 5.2±1.5 cryoapplications per patient (1.3±0.6 cryoapplications per vein). There were 4 patients (6.9%) with phrenic nerve injury (3 resolved during the index procedure ; 1 resolved at 6 months follow-up). One serious adverse device event was reported: femoral arterial embolism event occurring 2 weeks post index procedure (1.7%). Of the 56 patients that had complete 12-month follow-up, 43 (76.8%) were free from recurrent atrial arrhythmias. Conclusion: Initial multicenter clinical experience with the novel CB has demonstrated long-term safety and efficacy of PVI in patients with paroxysmal AF. Further studies are underway to confirm these findings.

paroxysmal atrial fibrillation ; pulmonary veins ; cryoballoon

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

369-369.

2021.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

European heart journal

0195-668X

1522-9645

Podaci o skupu

ESC Congress 2021 - The Digital Experience

poster

27.08.2021-30.08.2021

online

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost